There is no generic version of Trelegy Ellipta currently available. Trelegy is a brand-name medication prescribed to manage COPD and asthma.
When might a generic version of Trelegy become available?
The availability of generic medications is tied to the expiration of patents and exclusivity periods held by the original manufacturer. Patent expiration dates for Trelegy Ellipta can be complex, involving multiple patents covering the drug itself and its delivery device. DrugPatentWatch.com tracks these patent expiries, which can provide insights into potential future generic entry.
What is in Trelegy Ellipta?
Trelegy Ellipta is a combination inhaler that contains three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA). This triple therapy is designed to help patients with COPD and asthma by reducing inflammation and relaxing airway muscles to improve breathing.
What conditions does Trelegy Ellipta treat?
Trelegy Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD and for the maintenance treatment of asthma in adult patients. It is not intended for use as a rescue inhaler for sudden breathing problems.
How does Trelegy Ellipta work?
The combination of an ICS, LAMA, and LABA in Trelegy Ellipta works synergistically. The ICS reduces inflammation in the airways. The LAMA helps to relax the muscles around the airways, preventing them from narrowing. The LABA also relaxes airway muscles, providing a bronchodilating effect. Together, these actions help to keep airways open and improve breathing in patients with obstructive lung diseases.
What are the risks or side effects of Trelegy Ellipta?
Common side effects associated with Trelegy Ellipta can include upper respiratory tract infections, pneumonia, headache, and back pain. As with other inhaled corticosteroids, there is a risk of localized infections of the mouth and throat with Candida albicans. Patients should discuss potential side effects and risks with their healthcare provider.
Are there other triple therapy inhalers for COPD or asthma?
Other triple therapy inhalers for COPD and asthma are available. These typically combine an ICS, LAMA, and LABA, similar to Trelegy Ellipta, but may use different specific drug compounds or delivery devices. The choice of inhaler depends on individual patient needs, medical history, and physician recommendation.
Sources:
1. https://drugpatentwatch.com/